HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon
We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the Int...
Gespeichert in:
| Veröffentlicht in: | Antiviral therapy 2006-01, Vol.11 (5), p.575-579 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 579 |
|---|---|
| container_issue | 5 |
| container_start_page | 575 |
| container_title | Antiviral therapy |
| container_volume | 11 |
| creator | VERGNE, Laurence DIAGBOUGA, Serge HIEN, Hervé ZEKENG, Léopold DELAPORTE, Eric PEETERS, Martine KOUANFACK, Charles AGHOKENG, Avelin BUTEL, Christelle LAURENT, Christian NOUMSSI, Nathalie TARDY, Michele SAWADOGO, Adrien DRABO, Joseph |
| description | We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n = 1], M41L+T69S [n = 1]), four to non-NRTIs (NNRTIs; V106A/V [n = 1] and V1081 [n = 3]) and two to protease inhibitors (PIs; L33F [n = 2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes. |
| doi_str_mv | 10.1177/135965350601100511 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68840643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68840643</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-7c644e17a9bf2ebaca36159e498bc0863dc44273c96dbc1390e041723bfe94293</originalsourceid><addsrcrecordid>eNplkE1v1TAQRS0Eoo_CH2CBvIFd2vFn4iU8UVqpUje028hxJpEhsR-eRKX_njz1SV2wmsU992p0GPso4EKIur4UyjhrlAELQgAYIV6xnQQNlQTTvGa7I1AdiTP2jugXgGwcwFt2JqyzupFmx_5e3zxUgvdlHauCFGnxKSCf18UvMSfifs5p5AkfpyfeRz-mTNjzw5ZiWoh3OOSCnIKfYhqr9cAPJY_FzzMSj4l_W8vvmDy_8pS5Tz3f-xlLzuk9ezP4ifDD6Z6z-6vvP_fX1e3dj5v919sqqNosVR2s1ihq77pBYueDV1YYh9o1XYDGqj5oLWsVnO27IJQDBC1qqboBnZZOnbMvz7vbX39WpKWdIwWcJp8wr9TaptFgtdpA-QyGkokKDu2hxNmXp1ZAe_Td_u97K306ra_djP1L5SR4Az6fAH90NJRNb6QXrgFlnXHqH1C3iJo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68840643</pqid></control><display><type>article</type><title>HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>VERGNE, Laurence ; DIAGBOUGA, Serge ; HIEN, Hervé ; ZEKENG, Léopold ; DELAPORTE, Eric ; PEETERS, Martine ; KOUANFACK, Charles ; AGHOKENG, Avelin ; BUTEL, Christelle ; LAURENT, Christian ; NOUMSSI, Nathalie ; TARDY, Michele ; SAWADOGO, Adrien ; DRABO, Joseph</creator><creatorcontrib>VERGNE, Laurence ; DIAGBOUGA, Serge ; HIEN, Hervé ; ZEKENG, Léopold ; DELAPORTE, Eric ; PEETERS, Martine ; KOUANFACK, Charles ; AGHOKENG, Avelin ; BUTEL, Christelle ; LAURENT, Christian ; NOUMSSI, Nathalie ; TARDY, Michele ; SAWADOGO, Adrien ; DRABO, Joseph</creatorcontrib><description>We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n = 1], M41L+T69S [n = 1]), four to non-NRTIs (NNRTIs; V106A/V [n = 1] and V1081 [n = 3]) and two to protease inhibitors (PIs; L33F [n = 2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.1177/135965350601100511</identifier><identifier>PMID: 16964825</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Adult ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiretroviral Therapy, Highly Active ; Antiviral agents ; Biological and medical sciences ; Burkina Faso ; Cameroon ; Drug Resistance, Multiple, Viral - genetics ; Female ; HIV Infections - diagnosis ; HIV Infections - drug therapy ; HIV Infections - genetics ; HIV Protease - genetics ; HIV Protease Inhibitors - therapeutic use ; HIV-1 - genetics ; Human viral diseases ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Infectious diseases ; Male ; Medical sciences ; Middle Aged ; Mutation ; National Health Programs ; Pharmacology. Drug treatments ; Population Surveillance ; Reverse Transcriptase Inhibitors - therapeutic use ; RNA-Directed DNA Polymerase - genetics ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Antiviral therapy, 2006-01, Vol.11 (5), p.575-579</ispartof><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-7c644e17a9bf2ebaca36159e498bc0863dc44273c96dbc1390e041723bfe94293</citedby><cites>FETCH-LOGICAL-c375t-7c644e17a9bf2ebaca36159e498bc0863dc44273c96dbc1390e041723bfe94293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18036959$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16964825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VERGNE, Laurence</creatorcontrib><creatorcontrib>DIAGBOUGA, Serge</creatorcontrib><creatorcontrib>HIEN, Hervé</creatorcontrib><creatorcontrib>ZEKENG, Léopold</creatorcontrib><creatorcontrib>DELAPORTE, Eric</creatorcontrib><creatorcontrib>PEETERS, Martine</creatorcontrib><creatorcontrib>KOUANFACK, Charles</creatorcontrib><creatorcontrib>AGHOKENG, Avelin</creatorcontrib><creatorcontrib>BUTEL, Christelle</creatorcontrib><creatorcontrib>LAURENT, Christian</creatorcontrib><creatorcontrib>NOUMSSI, Nathalie</creatorcontrib><creatorcontrib>TARDY, Michele</creatorcontrib><creatorcontrib>SAWADOGO, Adrien</creatorcontrib><creatorcontrib>DRABO, Joseph</creatorcontrib><title>HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n = 1], M41L+T69S [n = 1]), four to non-NRTIs (NNRTIs; V106A/V [n = 1] and V1081 [n = 3]) and two to protease inhibitors (PIs; L33F [n = 2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.</description><subject>Adult</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Antiviral agents</subject><subject>Biological and medical sciences</subject><subject>Burkina Faso</subject><subject>Cameroon</subject><subject>Drug Resistance, Multiple, Viral - genetics</subject><subject>Female</subject><subject>HIV Infections - diagnosis</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - genetics</subject><subject>HIV Protease - genetics</subject><subject>HIV Protease Inhibitors - therapeutic use</subject><subject>HIV-1 - genetics</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>National Health Programs</subject><subject>Pharmacology. Drug treatments</subject><subject>Population Surveillance</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>RNA-Directed DNA Polymerase - genetics</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkE1v1TAQRS0Eoo_CH2CBvIFd2vFn4iU8UVqpUje028hxJpEhsR-eRKX_njz1SV2wmsU992p0GPso4EKIur4UyjhrlAELQgAYIV6xnQQNlQTTvGa7I1AdiTP2jugXgGwcwFt2JqyzupFmx_5e3zxUgvdlHauCFGnxKSCf18UvMSfifs5p5AkfpyfeRz-mTNjzw5ZiWoh3OOSCnIKfYhqr9cAPJY_FzzMSj4l_W8vvmDy_8pS5Tz3f-xlLzuk9ezP4ifDD6Z6z-6vvP_fX1e3dj5v919sqqNosVR2s1ihq77pBYueDV1YYh9o1XYDGqj5oLWsVnO27IJQDBC1qqboBnZZOnbMvz7vbX39WpKWdIwWcJp8wr9TaptFgtdpA-QyGkokKDu2hxNmXp1ZAe_Td_u97K306ra_djP1L5SR4Az6fAH90NJRNb6QXrgFlnXHqH1C3iJo</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>VERGNE, Laurence</creator><creator>DIAGBOUGA, Serge</creator><creator>HIEN, Hervé</creator><creator>ZEKENG, Léopold</creator><creator>DELAPORTE, Eric</creator><creator>PEETERS, Martine</creator><creator>KOUANFACK, Charles</creator><creator>AGHOKENG, Avelin</creator><creator>BUTEL, Christelle</creator><creator>LAURENT, Christian</creator><creator>NOUMSSI, Nathalie</creator><creator>TARDY, Michele</creator><creator>SAWADOGO, Adrien</creator><creator>DRABO, Joseph</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon</title><author>VERGNE, Laurence ; DIAGBOUGA, Serge ; HIEN, Hervé ; ZEKENG, Léopold ; DELAPORTE, Eric ; PEETERS, Martine ; KOUANFACK, Charles ; AGHOKENG, Avelin ; BUTEL, Christelle ; LAURENT, Christian ; NOUMSSI, Nathalie ; TARDY, Michele ; SAWADOGO, Adrien ; DRABO, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-7c644e17a9bf2ebaca36159e498bc0863dc44273c96dbc1390e041723bfe94293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Antiviral agents</topic><topic>Biological and medical sciences</topic><topic>Burkina Faso</topic><topic>Cameroon</topic><topic>Drug Resistance, Multiple, Viral - genetics</topic><topic>Female</topic><topic>HIV Infections - diagnosis</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - genetics</topic><topic>HIV Protease - genetics</topic><topic>HIV Protease Inhibitors - therapeutic use</topic><topic>HIV-1 - genetics</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>National Health Programs</topic><topic>Pharmacology. Drug treatments</topic><topic>Population Surveillance</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>RNA-Directed DNA Polymerase - genetics</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VERGNE, Laurence</creatorcontrib><creatorcontrib>DIAGBOUGA, Serge</creatorcontrib><creatorcontrib>HIEN, Hervé</creatorcontrib><creatorcontrib>ZEKENG, Léopold</creatorcontrib><creatorcontrib>DELAPORTE, Eric</creatorcontrib><creatorcontrib>PEETERS, Martine</creatorcontrib><creatorcontrib>KOUANFACK, Charles</creatorcontrib><creatorcontrib>AGHOKENG, Avelin</creatorcontrib><creatorcontrib>BUTEL, Christelle</creatorcontrib><creatorcontrib>LAURENT, Christian</creatorcontrib><creatorcontrib>NOUMSSI, Nathalie</creatorcontrib><creatorcontrib>TARDY, Michele</creatorcontrib><creatorcontrib>SAWADOGO, Adrien</creatorcontrib><creatorcontrib>DRABO, Joseph</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VERGNE, Laurence</au><au>DIAGBOUGA, Serge</au><au>HIEN, Hervé</au><au>ZEKENG, Léopold</au><au>DELAPORTE, Eric</au><au>PEETERS, Martine</au><au>KOUANFACK, Charles</au><au>AGHOKENG, Avelin</au><au>BUTEL, Christelle</au><au>LAURENT, Christian</au><au>NOUMSSI, Nathalie</au><au>TARDY, Michele</au><au>SAWADOGO, Adrien</au><au>DRABO, Joseph</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>11</volume><issue>5</issue><spage>575</spage><epage>579</epage><pages>575-579</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>We analysed whether mutations associated with resistance to antiretroviral (ARV) drugs circulate among treatment-naive HIV-1-infected individuals at a period when these drugs started to become more widely available in Africa. Overall, major resistance mutations in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, were observed in 16 treatment-naive individuals. Eight of the 97 patients tested in Burkina Faso bore mutations conferring resistance to one drug class of ARV drugs: two to nucleoside reverse transcriptase inhibitors (NRTIs; M41L [n = 1], M41L+T69S [n = 1]), four to non-NRTIs (NNRTIs; V106A/V [n = 1] and V1081 [n = 3]) and two to protease inhibitors (PIs; L33F [n = 2]). In Cameroon, resistance mutations were identified in 8 of 102 patients: three to PIs (M461/L [n = 2], L33F [n = 1]), three to NRTIs (T69N/T [n = 1], M184V [n = 1], A62V [n = 1]) and two to NNRTIs (P236L [n = 1], V1081 [n = 1]). It is important to note that not all genotypic drug-resistance algorithms give similar interpretations to the observed mutations. Population surveillance for ARV drug resistance is required and should be included in all implementation programmes.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>16964825</pmid><doi>10.1177/135965350601100511</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6535 |
| ispartof | Antiviral therapy, 2006-01, Vol.11 (5), p.575-579 |
| issn | 1359-6535 2040-2058 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68840643 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral Therapy, Highly Active Antiviral agents Biological and medical sciences Burkina Faso Cameroon Drug Resistance, Multiple, Viral - genetics Female HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - genetics HIV Protease - genetics HIV Protease Inhibitors - therapeutic use HIV-1 - genetics Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases Male Medical sciences Middle Aged Mutation National Health Programs Pharmacology. Drug treatments Population Surveillance Reverse Transcriptase Inhibitors - therapeutic use RNA-Directed DNA Polymerase - genetics Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
| title | HIV-1 drug-resistance mutations among newly diagnosed patients before scaling-up programmes in Burkina Faso and Cameroon |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T08%3A19%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HIV-1%20drug-resistance%20mutations%20among%20newly%20diagnosed%20patients%20before%20scaling-up%20programmes%20in%20Burkina%20Faso%20and%20Cameroon&rft.jtitle=Antiviral%20therapy&rft.au=VERGNE,%20Laurence&rft.date=2006-01-01&rft.volume=11&rft.issue=5&rft.spage=575&rft.epage=579&rft.pages=575-579&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.1177/135965350601100511&rft_dat=%3Cproquest_cross%3E68840643%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68840643&rft_id=info:pmid/16964825&rfr_iscdi=true |